BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-625@pharmaconomics
DTSTAMP:20260707T034519Z
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260414
SUMMARY:IDYA Phase 3 — darovasertib
DESCRIPTION:Phase 3 trial results for darovasertib in metastatic uveal melanoma are due Apr 13\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/d114952d8k.htm\n\nTrack it: https://www.pharmaconomics.com/e/625
URL:https://www.pharmaconomics.com/e/625
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IDYA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR